Obsidian Security Unveils AI Agent Defense to Secure SaaS Data Access
23.9.2025 16:00:00 EEST | Business Wire | Press release
Obsidian Security, leader in SaaS security, today announced the launch of SaaS AI agent defense, giving enterprises the first purpose-built solution to govern how AI agents access data in SaaS environments. With SaaS now one of the most targeted layers of the enterprise stack, Obsidian is closing the enterprise AI agent-to-SaaS blindspot, where unmanaged agentic AI integrations and excessive privileges can create cascading risk.
In the recent Salesforce attack (UNC6040), threat actors used voice phishing campaigns to obtain initial access and run bulk API queries for large-scale data theft and extortion. The Salesloft Salesforce supply chain breach (UNC6395) illustrated the fragility of SaaS-to-SaaS integrations where one compromised chatbot integration expanded into unauthorized access across Salesforce and downstream applications, including Google Workspace, Slack, Amazon S3, Microsoft Azure and other services at hundreds of enterprises. These attacks underscore the growing pattern of data exfiltration through SaaS integrations.
The rise of AI agents and its rapid pace of adoption further escalates the SaaS security challenge. Low-code and no-code platforms like Microsoft Copilot Studio, ChatGPT Enterprise, Salesforce Agentforce and n8n let any employee build and deploy agents that act inside SaaS applications, chaining tasks, querying data, and executing decisions autonomously without oversight. These agents often carry broad privileges, long-lasting tokens and move sensitive business data at machine speed. If compromised, they can rapidly leak data, escalate access and move laterally across connected SaaS applications, causing widespread damage.
“The AI agent shift is well underway, and we’re seeing the risks firsthand as we help our customers scale adoption securely,” said Hasan Imam, CEO at Obsidian. “87% of enterprises have Microsoft Copilot enabled, more than half the agents access sensitive data, 90% are over-permissioned, and move 16 times more data than humans accessing SaaS applications. These risks are not theoretical, they’re active risks inside enterprises today, often without their awareness.”
Traditional security tools lack visibility into machine-driven activity, cannot contextualize underlying privileges and are unable to enforce controls at the speed and scale of autonomous agents.
“The difference between a major intrusion and successful containment comes down to speed,” said Sunil Seshadri, EVP and CSO at HealthEquity and ex-CISO at Wells Fargo, Visa and NYSE. “Most security teams already struggle to react to incidents fast enough and AI agents raise the stakes even higher. They can trigger workflows across multiple SaaS apps in seconds, often without anyone noticing until damage is done. Obsidian flips that dynamic by detecting issues in near real-time, faster than most security tools are able to, giving teams the chance to shut them down before they spiral out of control.” As a board member of Obsidian Security, Sunil provides strategic guidance in building the industry-leading SaaS and AI Agent Security for Global 2000.
Protecting SaaS Environments from AI Agent Risks
Obsidian is uniquely positioned to address the security risks created by autonomous AI agents in SaaS environments. At its core is the industry’s most comprehensive SaaS threat dataset repository – over 500 curated real-world threat intelligence, enriched with browser-based activity capture and deep SaaS and AI integrations. This intelligence powers the Obsidian Knowledge Graph, a continuously learning model that unifies user and agent activity, identity privileges, and workflows across SaaS and SaaS managed agentic AI platforms into a single correlated view. This live map gives security teams real-time visibility and context to govern agentic AI usage and stop unauthorized agents and behavior inside SaaS environments, where risks emerge and propagate.
“In customer deployments, our continuously learning Knowledge Graph revealed that AI agents in SaaS environments were typically granted ten times more permissions than needed when mapped against real user privileges and entitlements – visibility only Obsidian can deliver,” said Khanh Tran, Chief Product Officer at Obsidian. “By connecting popular AI platforms like Microsoft Copilot Studio, n8n, Salesforce Agentforce, and ChatGPT Enterprise with the Obsidian Knowledge Graph, security teams can finally see what agents are doing in SaaS. That intel means they can stop risks before they spread and empower users to innovate faster without sacrificing security or governance."
This product release is a major step forward in enabling enterprises securely scale AI agent development. Key capabilities in the latest release include:
- Unmatched Visibility & Access Cleanup: Get a live inventory of every AI agent, including its privileges, SaaS connections, and actions, to eliminate excessive or risky access and enable full lifecycle oversight.
- Continuous Observability & Compliance: Map AI agent access across SaaS and trace it to the data touched, with correlated audit trails that link entitlements directly to actions.
- Prevent Misuse & Privilege Escalation: Detect and block agents attempting to exploit trust chains, misuse access, or escalate privileges before damage cascades across SaaS environments.
Current integrations to AI platforms include Microsoft Copilot Studio, ChatGPT Enterprise, Salesforce Agentforce and n8n, with more underway.
To help enterprises quickly understand and assess their exposure, Obsidian is offering a free assessment to its SaaS AI agent defense capabilities for 30 days. For more information and to sign up, visit www.obsidiansecurity.com
Additional Resources
- Learn more about our latest capabilities
- Read the launch blog for deeper coverage
- Watch a demo
- Follow us: X | LinkedIn
About Obsidian Security
Obsidian Security is the leading SaaS security platform, trusted by global enterprises like Snowflake, T-Mobile, and S&P Global. We protect over 250 global organizations, including many of the world’s largest Fortune 1000 and Global 2000 companies, with data center availability in North America, EMEA, and APAC—Saudi Arabia coming soon. Backed by top investors including Greylock, Norwest Venture Partners, and IVP, we’re closing a critical gap: securing the SaaS and AI tools that organizations rely on. Our platform reduces risk, detects and responds to threats, and prevents breaches at the source. Obsidian was built by leaders who redefined endpoint and identity security at CrowdStrike, Okta, Cylance, and Carbon Black.
For more information, visit www.obsidiansecurity.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250923529562/en/
Contacts
press@obsidiansecurity.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom